

---

# State of the ACTG

## June, 2017

**Daniel R. Kuritzkes, MD**  
**Co-Principal Investigator and Chair**  
**AIDS Clinical Trials Group**

# Progress on ACTG Trials

---

- **9 studies completed accrual**
  - **A5316 (Vaginal Ring & ART PK Study)**
  - **A5321 (ACTG HIV Reservoirs Cohort-AHRC)**
  - **A5327 (Sofosbuvir for Acute HCV)**
  - **A5334s (A5329 PK Substudy)**
  - **A5346 (Sitagliptin)**
  - **A5348 (LDV/SOF for HCV Retreatment)**
  - **A5350 (Effect of Visbiome)**
  - **A5352s (Epithelial Barrier Substudy of A5350)**
  - **A5353 (Dolutegravir plus Lamivudine)**

# Progress on ACTG Trials

---

- **12 studies completed follow-up**
  - **A5225 (Fluconazole for Cryptococcal Meningitis)**
  - **A5282 (HPV Test-and-Treat)**
  - **A5308 (ART for HIV Controllers)**
  - **A5314 (Methotrexate)**
  - **A5316 (Vaginal Ring & ART PK Study)**
  - **A5325 (Isotretinoin & CD4 Recovery)**
  - **A5330s (Gut Mucosal Substudy of A5325)**
  - **A5334s (A5329 PK Substudy)**
  - **A5340 (Phase I Study of VRC01 During ATI)**
  - **A5342 (Impact of VRC01 on HIV Persistence)**
  - **A5346 (Sitagliptin)**
  - **A5348 (LDV/SOF for HCV Retreatment)**

# Progress on ACTG Trials

---

- **12 studies completed follow-up**
  - **A5348 (LDV/SOF for HCV Retreatment)**
  - **A5346 (Sitagliptin)**
  - **A5340 (Phase I Study of VRC01 During ATI)**
  - **A5342 (Impact of VRC01 on HIV Persistence)**
  - **A5334s (A5329 PK Substudy)**
  - **A5330s (Gut Mucosal Substudy of A5325)**
  - **A5325 (Isotretinoin & CD4 Recovery)**
  - **A5316 (Vaginal Ring & ART PK Study)**
  - **A5314 (Methotrexate)**
  - **A5308 (ART for HIV Controllers)**
  - **A5282 (HPV Test-and-Treat)**
  - **A5225 (High-dose fluconazole for Crypto Meningitis)**

# Progress on ACTG Trials

---

- **5 studies opened to accrual**
  - **A5343 (Bedaquiline-Delamanid Interaction Study)**
  - **A5345 (HIV Rebound & Control Biomarkers)**
  - **A5347s (Reservoir Sampling Substudy of A5345)**
  - **A5354 (EARLIER)**
  - **A5361s (PREPARE Substudy of REPRIEVE)**

# ACTG Accrual (June, 2016– May, 2017)

---

**2,421 enrolled into interventional trials\***

**744 enrolled into other observational studies**

**474 enrolled into A5128 or A5243**

---

**3,649 participants enrolled across all studies**

**1,722 participants enrolled at international sites**

**1,924 participants enrolled at US sites**

**3 participants enrolled at non-ACTG CRSs**

**\*Includes 1,273 enrolled in Reprieve**

# ACTG Abstracts and Publications

---

- **46 abstracts presented at 13 meetings**
- **61 manuscripts published or in press in 26 journals**
  - AIDS 9
  - Journal of Infectious Diseases 9
  - JAIDS 5
  - Antiviral Therapy 4
  - Clinical Infectious Diseases 4
  - AIDS Res Hum Retrovirol 3
  - Open Forum Infectious Disease 3
  - (Antimicrobial Agents and Chemotherapy, Biometrics, J Clin Invest, Lancet HIV, N Engl J Med, PLoS Pathogens, etc.)